TScan Therapeutics Files 10-Q for Q1 2025
Ticker: TCRX · Form: 10-Q · Filed: 2025-05-06T00:00:00.000Z
Sentiment: neutral
Topics: 10-Q, quarterly-report, biotechnology
TL;DR
**TScan Therapeutics Q1 2025 10-Q filed. Financials and ops update.**
AI Summary
TScan Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported its financial results and provided updates on its business operations. Key financial data and operational highlights are detailed within the filing, which was submitted on May 6, 2025.
Why It Matters
This filing provides investors with a quarterly update on TScan Therapeutics' financial health and operational progress, crucial for understanding the company's trajectory in the biotechnology sector.
Risk Assessment
Risk Level: medium — As a biotechnology company, TScan Therapeutics faces inherent risks related to clinical trials, regulatory approvals, and market competition.
Key Numbers
- 20250331 — Period End Date (The end of the reporting quarter.)
- 20250506 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
Key Players & Entities
- TScan Therapeutics, Inc. (company) — Filer of the 10-Q
- 0000950170-25-063968 (other) — Accession Number for the filing
- 20250331 (date) — Period of report
- 20250506 (date) — Filing date
- 880 WINTER STREET (address) — Business and mail address
- WALTHAM, MA (location) — City and State of business address
- 02451 (postal_code) — ZIP code of business address
- 857-399-9500 (phone_number) — Business phone number
FAQ
What is the reporting period for this 10-Q filing?
The reporting period for this 10-Q filing is March 31, 2025.
When was this 10-Q filed with the SEC?
This 10-Q was filed on May 6, 2025.
What is the company's name and Central Index Key (CIK)?
The company's name is TScan Therapeutics, Inc., and its Central Index Key is 0001783328.
What is the business address of TScan Therapeutics, Inc.?
The business address is 880 WINTER STREET, WALTHAM, MA 02451.
What is the Standard Industrial Classification (SIC) code for TScan Therapeutics, Inc.?
The SIC code is 2836, which corresponds to BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).
From the Filing
0000950170-25-063968.txt : 20250506 0000950170-25-063968.hdr.sgml : 20250506 20250506073020 ACCESSION NUMBER: 0000950170-25-063968 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 52 CONFORMED PERIOD OF REPORT: 20250331 FILED AS OF DATE: 20250506 DATE AS OF CHANGE: 20250506 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TScan Therapeutics, Inc. CENTRAL INDEX KEY: 0001783328 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 825282075 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-40603 FILM NUMBER: 25915245 BUSINESS ADDRESS: STREET 1: 880 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 857-399-9500 MAIL ADDRESS: STREET 1: 880 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 10-Q 1 tcrx-20250331.htm 10-Q 10-Q false --12-31 0001783328 Q1 http://www.tscan.com/20250331#CollaborationAndLicenseRevenue http://www.tscan.com/20250331#CollaborationAndLicenseRevenue http://fasb.org/srt/2024#ChiefExecutiveOfficerMember 1 0001783328 2023-12-31 0001783328 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2025-03-31 0001783328 us-gaap:MoneyMarketFundsMember 2025-03-31 0001783328 tcrx:VotingCommonStockMember tcrx:FollowOnOfferingMember 2023-06-01 2023-06-01 0001783328 tcrx:PreFundedWarrantsMember 2025-03-31 0001783328 us-gaap:USGovernmentDebtSecuritiesMember 2025-03-31 0001783328 tcrx:SiliconValleyBankMember 2025-01-01 2025-03-31 0001783328 2025-01-01 2025-03-31 0001783328 tcrx:VotingCommonStockMember 2025-04-30 0001783328 tcrx:FacilityRelatedAndOtherMember tcrx:ReportableSegmentMember 2024-01-01 2024-03-31 0001783328 us-gaap:ConvertibleDebtSecuritiesMember 2024-01-01 2024-03-31 0001783328 tcrx:ReportableSegmentMember tcrx:ClinicalStudiesMember 2024-01-01 2024-03-31 0001783328 us-gaap:MoneyMarketFundsMember 2024-12-31 0001783328 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001783328 tcrx:PreFundedWarrantsMember 2024-12-27 2024-12-27 0001783328 tcrx:ReportableSegmentMember 2025-01-01 2025-03-31 0001783328 us-gaap:RetainedEarningsMember 2025-03-31 0001783328 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001783328 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001783328 us-gaap:NonvotingCommonStockMember 2025-04-30 0001783328 tcrx:PreFundedWarrantsMember 2023-06-01 0001783328 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001783328 us-gaap:CommonStockMember tcrx:VotingCommonStockMember 2023-12-31 0001783328 tcrx:SiliconValleyBankMember 2024-12-20 0001783328 us-gaap:USGovernmentDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member 2025-03-31 0001783328 tcrx:LaboratorySuppliesResearchMaterialsAndStudiesMember tcrx:ReportableSegmentMember 2025-01-01 2025-03-31 0001783328 tcrx:TrancheTwoMember tcrx:SiliconValleyBankMember 2024-12-20 0001783328 tcrx:SiliconValleyBankMember 2024-12-20 2024-12-20 0001783328 tcrx:VotingCommonStockMember tcrx:PreFundedWarrantsMember 2024-04-24 2024-04-24 0001783328 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0001783328 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2024-12-31 0001783328 us-gaap:CommonStockMember tcrx:VotingCommonStockMember 2024-03-31 0001783328 us-gaap:NonvotingCommonStockMember us-gaap:CommonStockMember 2025-03-31 0001783328 tcrx:VotingCommonStockMember tcrx:WedbushSecuritiesIncMember tcrx:SalesAgreementMember 2023-05-16 2025-03-31 0001783328 tcrx:VotingCommonStockMember tcrx:FollowOnOfferingMember 2024-04-24 0001783328 tcrx:StockBasedCompensationMember tcrx:ReportableSegmentMember 2025-01-01 2025-03-31 0001783328 tcrx:PersonnelExpensesMember tcrx:ReportableSegmentMember 2025-01-01 2025-03-31 0001783328 tcrx:K2HealthVenturesMember 2024-12-20 2024-12-20 0001783328 tcrx:EmployeeStockPurchasePlanMember 2025-01-01 2025-03-31 0001783328 2024-04-24 2024-04-24 0001783328 tcrx:AmgenAgreementMember tcrx:AmgenIncMember 2024-01-01 2024-03-31 0001783328 tcrx:AmgenAgreeme